Treatment Patterns and Clinical Outcomes Among Patients With Advanced Renal Cell Carcinoma (aRCC) Receiving Systemic First-line (1st Line) Anti-cancer Treatment Under Daily Routine in Germany: Retrospective Medical Chart Review (RENALISTIC Study).

Pfizer

Status: Terminated

Conditions: Carcinoma, Renal Cell

Study type: Observational

Funder types: Industry

Identifiers

NCT05534789

A4061099

Details and patient eligibility

About

The purpose of this study is to learn about the treatments used in for advanced renal cell carcinoma as well as effectiveness of these treatments in the real world. Study participants must be:

At least 18 years of age or older. Confirmed renal cell carcinoma Received first line treatment

Enrollment: 106 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Participants diagnosed with locally advanced or metastatic renal cell carcinoma
• Participants with full medical information is available regarding all treatments before, during and after 1st line

Exclusion Criteria:

Trial design